Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to compare two different approaches to surgery for children and adults with osteosarcoma (bone cancer) that has spread (metastasized) to the lungs. Participants will be randomly assigned to one of two techniques:
Researchers want to know if eating a plant-based diet and taking certain nutritional supplements may be helpful for reducing the risk of progression to multiple myeloma in people with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). People with MGUS and SMM have an abnormal protein called the M protein in their blood and are at risk of developing multiple myeloma.
The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.
In this study, researchers want to find out how different amounts of aerobic training might improve cardiorespiratory fitness in people while they are treated for breast cancer. Cardiorespiratory fitness is important for the health of people receiving treatment for breast cancer. Aerobic exercise stimulates and strengthens the heart and lungs and improves how the body uses oxygen.
The standard treatment for head and neck cancers includes high-dose radiation therapy and chemotherapy, but it commonly causes side effects. In this study, researchers are assessing a treatment for head and neck cancer that starts with standard high-dose radiation therapy and chemotherapy and then reduces the doses of both treatments. Patients then have surgery to remove lymph nodes and tissue from the neck area.
The purpose of this study is to assess the safety and effectiveness of a specialized light treatment for children and adults with chronic graft-versus host disease (GVHD) of the mouth (oral GVHD) that has not improved after standard treatment. GVHD is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body and cause serious health problems. Oral GVHD can cause mouth inflammation, pain, and sores.
The purpose of this study is to find the highest dose of the investigational drug XMT-1660 that can be given safely in people with advanced triple-negative breast cancer (TNBC) that persists despite prior chemotherapy. TNBC includes breast cancers that do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.
In this study, researchers want to see if adding stereotactic body radiation therapy (SBRT) to standard drug therapy is effective for people with estrogen receptor (ER)-positive HER2-positive oligometastatic breast cancer that has gotten worse at one metastatic site despite medical treatment. Oligometastatic breast cancer is cancer that has spread to a small number of parts of the body. SBRT delivers extremely precise, very intense doses of radiation to cancer cells.
The purpose of this study is to assess the safety and effectiveness of the investigational drug ZEN003694 in people with advanced squamous cell lung cancer that continues to grow despite treatment and contains multiple copies of a gene called NSD3. ZEN003694 blocks a group of proteins called BET, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of lung cancer. ZEN003694 is taken orally (by mouth).
